GlassScriptPhysician profile
Mitchell Lynn Cardwell
NPI 1790735546
$1,063.47
in general payments reported to CMS, 2019-2025
24 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.95 · 2020: $184 · 2021: $199 · 2022: $112 · 2023: $151 · 2024: $238 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $163.02 | 2019-2025 | |
| Pfizer INC. | $155.62 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $77.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.34 | 2020-2025 | Airsupra, Breztri |
| Inspire Medical Systems, INC. | $71.88 | 2024 | Inspire |
| Amgen INC. | $55.45 | 2020-2022 | |
| Novo Nordisk INC | $53.09 | 2020-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $52.81 | 2020-2024 | Uzedy, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.46 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $45.45 | 2020-2021 | |
| Exact Sciences Corporation | $39.17 | 2023-2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $32.87 | 2022 | |
| Glaxosmithkline, LLC. | $23.18 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $19.47 | 2023 | Belsomra, Verquvo |
| Biogen, INC. | $17.63 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.66 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.04 | 2023 | Xywav |
| E.R. Squibb & Sons, L.L.C. | $15.41 | 2024 | Eliquis |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Acadia Pharmaceuticals INC | $15.09 | 2021 | |
| Genzyme Corporation | $15.03 | 2023 | |
| Lilly USA, LLC | $14.71 | 2025 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $11.93 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cardwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.